

DESCRIPTION

Source *E. coli*-derived human GM-CSF protein
Ala18-Glu144
Accession # P04141.1
Produced using non-animal reagents in an animal-free laboratory.

N-terminal Sequence Analysis Ala18

Predicted Molecular Mass 14 kDa

SPECIFICATIONS

SDS-PAGE 13 kDa, reducing conditions

Activity Measured in a cell proliferation assay using TF-1 human erythroleukemic cells. Kitamura, T. *et al.* (1989) J. Cell Physiol. **140**:323.
The ED₅₀ for this effect is 6-30 pg/mL.
The specific activity of recombinant human GM-CSF is >1.0 x 10⁷ IU/mg, which is calibrated against the human GM-CSF WHO International Standard (NIBSC code: 88/646).

Endotoxin Level <1.0 EU per 1 µg of the protein by the LAL method.

Purity >97%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Formulation Lyophilized from a 0.2 µm filtered solution in PBS. See Certificate of Analysis for details.

PREPARATION AND STORAGE

Reconstitution Reconstitute at 0.2 mg/mL in sterile PBS.


Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.


DATA

Bioactivity



Recombinant Human GM-CSF, Animal-Free Protein Bioactivity
Animal-Free™ Recombinant Human GM-CSF (Catalog # AFL215) stimulates cell proliferation of the TF-1 human erythroleukemic cell line. The ED₅₀ for this effect is 6-30 pg/mL.

SDS-PAGE



Recombinant Human GM-CSF, Animal-Free Protein SDS-PAGE
1 µg/lane of Animal-Free™ Recombinant Human IL-4 (Catalog # AFL215) was resolved with SDS-PAGE under reducing (R) conditions and visualized by silver staining, showing a single band at 13 kDa.

BACKGROUND

GM-CSF was initially characterized as a factor that can support the *in vitro* colony formation of granulocyte-macrophage progenitors. It is also a growth factor for erythroid, megakaryocyte, and eosinophil progenitors. GM-CSF is produced by a number of different cell types (including T cells, B cells, macrophages, mast cells, endothelial cells, fibroblasts, and adipocytes) in response to cytokine or inflammatory stimuli. On mature hematopoietic cells, GM-CSF is a survival factor for and activates the effector functions of granulocytes, monocytes/macrophages, and eosinophils (1, 2). GM-CSF promotes a Th1 biased immune response, angiogenesis, allergic inflammation, and the development of autoimmunity (3 - 5). It shows clinical effectiveness in ameliorating chemotherapy-induced neutropenia, and GM-CSF transfected tumor cells are utilized as cancer vaccines (6, 7). The 22 kDa glycosylated GM-CSF, similar to IL-3 and IL-5, is a cytokine with a core of four bundled α -helices (8 - 12). Mature human GM-CSF shares 63%-70% amino acid sequence identity with canine, feline, porcine, and rat GM-CSF and 54% with mouse GM-CSF. GM-CSF exerts its biological effects through a heterodimeric receptor complex composed of GM-CSF R α /CD116 and the signal transducing common β chain (CD131) which is also a component of the high-affinity receptors for IL-3 and IL-5 (13, 14). In addition, GM-CSF binds a naturally occurring soluble form of GM-CSF R α (15). Human GM-CSF is active on canine and feline cells but not on murine cells (16-18).

References:

1. Martinez-Moczygemba, M. and D.P. Huston (2003) J. Allergy Clin. Immunol. **112**:653.
2. Barreda, D.R. *et al.* (2004) Dev. Comp. Immunol. **28**:509.
3. Eksioglu, E.A. *et al.* (2007) Exp. Hematol. **35**:1163.
4. Cao, Y. (2007) J. Clin. Invest. **117**:2362.
5. Fleetwood, A.J. *et al.* (2005) Crit. Rev. Immunol. **25**:405.
6. Heuser, M. *et al.* (2007) Semin. Hematol. **44**:148.
7. Hege, K.M. *et al.* (2006) Int. Rev. Immunol. **25**:321.
8. Kaushansky, K. *et al.* (1992) Biochemistry **31**:1881.
9. Diederichs, K. *et al.* (1991) Science **254**:1779.
10. Cantrell, M.A. *et al.* (1985) Proc. Natl. Acad. Sci. **82**:6250.
11. Lee, F. *et al.* (1985) Proc. Natl. Acad. Sci. **82**:4360.
12. Wong, G.G. *et al.* (1985) Science **228**:810.
13. Onetto-Pothier, N. *et al.* (1990) Blood **75**:59.
14. Hayashida, K. *et al.* (1990) Proc. Natl. Acad. Sci. **87**:9655.
15. Pelley, J.L. *et al.* (2007) Exp. Hematol. **35**:1483.
16. Hogge, G.S. *et al.* (1990) Cancer Gene Ther. **6**:26.
17. Sprague, W.S. *et al.* (2005) J. Comp. Pathol. **133**:136.
18. Shanafelt, A.B. *et al.* (1991) J. Biol. Chem. **266**:13804.

MANUFACTURING SPECIFICATIONS

Animal-Free Manufacturing Conditions

Our dedicated controlled-access animal-free laboratories ensure that at no point in production are the products exposed to potential contamination by animal components or byproducts. Every stage of manufacturing is conducted in compliance with R&D Systems' stringent Standard Operating Procedures (SOPs). Production and purification procedures use equipment and media that are confirmed animal-free.

Production

- All molecular biology procedures use animal-free media and dedicated labware.
- Dedicated fermentors are utilized in committed animal-free areas.

Purification

- Protein purification columns are animal-free.
- Bulk proteins are filtered using animal-free filters.
- Purified proteins are stored in animal-free containers in a dedicated cold storage room.

Quality Assurance

- Low Endotoxin Level.
- No impairment of biological activity.
- High quality product obtained under stringent conditions.
- For *ex vivo* research or bioproduction, [additional documentation](#) can be provided.

[Please read our complete Animal-Free Statement](#)